Literature DB >> 15276814

Effect of a beta-3 agonist on food intake in two strains of rats that differ in susceptibility to obesity.

Christy L White1, Yuri Ishihara, Travis L Dotson, David A Hughes, George A Bray, David A York.   

Abstract

CONTEXT: Beta-3 agonists acutely reduce food intake, but the mechanism is not well understood.
OBJECTIVE: To evaluate the effect of a beta3 agonist on food intake in two strains of rats that differ in their sensitivity to becoming obese while eating a high-fat (HF) diet.
METHODS: Male Osborne-Mendel (OM) and S5B/Pl (S5B) rats were treated with a beta3-adrenergic agonist (CL 316,243) at 8 weeks of age, after an adaptation to either an HF (56% fat energy) or a low-fat (LF; 10% fat energy) diet that was equicaloric for protein (24% energy). Ad-lib-fed rats were injected intraperitoneally with CL 316,243, at doses of 0.03, 0.1, 0.3, 1.0 or 3.0 mg/kg, or with vehicle at the beginning of the dark cycle. Food intake was measured at 1, 3, 6 and 24 h after injections.
RESULTS: The beta3 agonist CL 316,243 significantly decreased food intake at all timepoints in both strains of rats eating both diets. However, this inhibition of food intake was significantly greater in the S5B rat. CL 316,243 significantly decreased serum leptin and serum glucose in both the OM and the S5B rats, and again, the inhibition was greater in the S5B rat. Whereas CL 316,243 increased serum insulin levels in the OM rat, it decreased them in the S5B rat on an LF diet. In a second experiment, chow-fed rats were implanted with vascular ports into the jugular vein and allowed to recover. When CL 316,243 was injected into the animals that were fasted overnight, rats of both strains significantly increased their serum insulin at 30 min, but the increase was much more pronounced in the S5B rat. Serum glucose was decreased significantly at both the 30- and 60-min timepoints in the OM rat and at 30 min in the S5B rat.
CONCLUSION: These experiments demonstrate that a beta3 agonist (CL 316,243) has a much greater effect in a strain of rats that resist fat-induced obesity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276814     DOI: 10.1016/j.physbeh.2004.04.059

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  5 in total

1.  Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB₁ receptor blockade.

Authors:  Luigi Bellocchio; Edgar Soria-Gómez; Carmelo Quarta; Mathilde Metna-Laurent; Pierre Cardinal; Elke Binder; Astrid Cannich; Anna Delamarre; Martin Häring; Mar Martín-Fontecha; David Vega; Thierry Leste-Lasserre; Dusan Bartsch; Krisztina Monory; Beat Lutz; Francis Chaouloff; Uberto Pagotto; Manuel Guzman; Daniela Cota; Giovanni Marsicano
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

2.  Significance of Mouse Models in Dissecting the Mechanism of Human Eosinophilic Gastrointestinal Diseases (EGID).

Authors:  Anil Mishra
Journal:  J Gastroenterol Hepatol Res       Date:  2013

3.  Prolonged treatment with the beta3-adrenergic agonist CL 316243 induces adipose tissue remodeling in rat but not in guinea pig: 1) fat store depletion and desensitization of beta-adrenergic responses.

Authors:  C Ferrand; A Redonnet; D Prévot; C Carpéné; C Atgié
Journal:  J Physiol Biochem       Date:  2006-06       Impact factor: 5.080

4.  Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat.

Authors:  Juan Suárez; Patricia Rivera; Sergio Arrabal; Ana Crespillo; Antonia Serrano; Elena Baixeras; Francisco J Pavón; Manuel Cifuentes; Rubén Nogueiras; Joan Ballesteros; Carlos Dieguez; Fernando Rodríguez de Fonseca
Journal:  Dis Model Mech       Date:  2013-10-23       Impact factor: 5.758

5.  Systemic bone loss following myocardial infarction in mice.

Authors:  Priscilla M Tjandra; Manali P Paralkar; Benjamin Osipov; Yi-Je Chen; Fengdong Zhao; Crystal M Ripplinger; Blaine A Christiansen
Journal:  J Orthop Res       Date:  2020-10-06       Impact factor: 3.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.